Deguchi K, Yokota N, Koguchi M, Nakane Y, Suzuki Y, Suzuki K, Fukayama S, Ishihara R, Oda S
Section of Studies, Tokyo Clinical Research Center.
Jpn J Antibiot. 1992 Oct;45(10):1312-8.
Antibacterial effects of combination use of arbekacin (ABK) with cefmetazole (CMZ) or flomoxef (FMOX) were evaluated against methicillin-resistant Staphylococcus aureus (MRSA) and the following results were obtained. 1. Antibacterial effects of combinations of ABK with CMZ and with FMOX were equally potent against MRSA at clinically expected 1 MIC of ABK in blood. However, at a sub MIC of ABK different effects were observed between the 2 combinations. The former combination was slightly less effective than the latter. 2. In either combination the potency of the antibacterial activity was less dependent on the concentration of CMZ or FMOX, but was strongly dependent on ABK concentrations. These results suggest that antibacterial effects of the combinations were highly dependent on antibacterial potency and concentration of ABK as previously reported for combinations of ABK with other drugs. 3. It appears that the antibacterial activity of the combination of the sub MIC of ABK with a beta-lactam is an important point in considering the effectiveness of a combination therapy.
评估了阿贝卡星（ABK）与头孢美唑（CMZ）或氟氧头孢（FMOX）联合使用对耐甲氧西林金黄色葡萄球菌（MRSA）的抗菌效果，结果如下：1. 在临床上预期的血液中ABK的1倍最低抑菌浓度（MIC）下，ABK与CMZ及与FMOX联合使用的抗菌效果对MRSA同样有效。然而，在ABK的亚MIC浓度下，两种联合用药观察到不同的效果。前一种联合用药的效果略低于后一种。2. 在任何一种联合用药中，抗菌活性的效力对CMZ或FMOX的浓度依赖性较小，但对ABK的浓度依赖性很强。这些结果表明，联合用药的抗菌效果高度依赖于ABK的抗菌效力和浓度，正如之前报道的ABK与其他药物联合使用的情况。3. 似乎ABK的亚MIC浓度与β-内酰胺类药物联合使用时的抗菌活性是考虑联合治疗有效性的一个重要因素。
